Laurus Labs Share Price
Laurus Labs Ltd.
Performance of Laurus Labs Shares 
Open Price
Prev. Close
Volume
Value
About Laurus Labs
Laurus labs is an innovation-driven¸ people-centric & client-focused organization offering a broad and integrated portfolio of products & services to the global pharmaceutical industry. Equipped with a world-class infrastructure manned by best-in-class personnel & driven by the core values of knowledge, innovation and excellence, within a relatively short period, Laurus labs emerged as a segment-leading manufacturer of high quality APIs, a preferred partner for NCE development & manufacture & a trusted source of specialty ingredients for the nutraceutical industry. Given the strengths, capabilities & experience, Laurus Labs is uniquely positioned to help its clients in their endeavor of ‘quicker to market’ & thus contributing towards improving access to quality & affordable healthcare worldwide. Click Here
to know today’s Laurus Labs Ltd’s share price.
Fundamentals of Laurus Labs Shares
Market Cap |
P/E Ratio |
P/B Ratio |
Industry P/E |
|---|---|---|---|
Rs. 16288.80 Cr |
2.58 |
1.90 |
64.26 |
ROE |
EPS (TTM) |
Dividend Yield |
Book Value |
|---|---|---|---|
15.72 % |
13.96 |
0.77 % |
74.01 |
Similar Stocks
FAQ’s
How to buy Laurus Labs Ltd. shares?
All you have to do to buy Laurus Labs Ltd. share is download Nuuu app, create a demat account, and get your KYC documents verified online.
Can I buy Laurus Labs Ltd. shares?
Yes you can buy Laurus Labs Ltd. shares, all you need is to have a verified demat account with Nuuu. And enjoy benefits like free brokerage credits and more.
What is the Market Cap of Laurus Labs Ltd. shares?
As of 20 Mar`23 the Market Cap of Laurus Labs Ltd. is 16288.80.
What is the PE and PB ratio of Laurus Labs Ltd. stock?
As of 20 Mar`23 the PE is 2.58 and PB is 1.90.
Laurus Labs - Quaterly Results
Publish Date: 21/10/2022
The sales moved up 27.37% to Rs. 14981.60 millions for the September 2022 quarter as compared to Rs. 11762.00 millions during the year-ago period.A slim rise of 15.08% was recorded in the Net profit for the quarter ended September 2022 to Rs. 2274.40 millions From Rs. 1976.30 millions.Operating Profit saw a handsome growth to 4301.40 millions from 3383.10 millions in the quarter ended September 2022.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202209 | 202109 | % Var | 202209 | 202109 | % Var | 202203 | 202103 | % Var | |
| Sales | 14981.60 | 11762.00 | 27.37 | 29934.10 | 23968.00 | 24.89 | 47070.40 | 47687.20 | -1.29 |
| Other Income | 41.00 | 45.00 | -8.89 | 70.30 | 120.70 | -41.76 | 215.50 | 273.20 | -21.12 |
| PBIDT | 4301.40 | 3383.10 | 27.14 | 8512.50 | 7089.40 | 20.07 | 13067.50 | 15371.90 | -14.99 |
| Interest | 379.10 | 205.90 | 84.12 | 654.10 | 456.30 | 43.35 | 958.60 | 659.20 | 45.42 |
| PBDT | 3922.30 | 3177.20 | 23.45 | 7858.40 | 6633.10 | 18.47 | 12108.90 | 14712.70 | -17.70 |
| Depreciation | 755.50 | 593.30 | 27.34 | 1415.50 | 1148.20 | 23.28 | 2354.80 | 1966.40 | 19.75 |
| PBT | 3166.80 | 2583.90 | 22.56 | 6442.90 | 5484.90 | 17.47 | 9754.10 | 12746.30 | -23.48 |
| TAX | 892.40 | 607.60 | 46.87 | 1852.40 | 1287.80 | 43.84 | 2253.20 | 3185.20 | -29.26 |
| Deferred Tax | 0.80 | -59.60 | -101.34 | -69.00 | 114.70 | -160.16 | -61.00 | -164.60 | -62.94 |
| PAT | 2274.40 | 1976.30 | 15.08 | 4590.50 | 4197.10 | 9.37 | 7500.90 | 9561.10 | -21.55 |
| Equity | 1074.70 | 1073.20 | 0.14 | 1074.70 | 1073.20 | 0.14 | 1074.70 | 1073.20 | 0.14 |
| PBIDTM(%) | 28.71 | 28.76 | -0.18 | 28.44 | 29.58 | -3.86 | 27.76 | 32.23 | -13.88 |
Laurus Labs - Quaterly Results
Publish Date: 30/01/2023
The Turnover for the quarter ended December 2022 of Rs. 15007.00 millions increase by 60.92% from Rs. 9325.80 millions.Net profit surges 82.35% to Rs. 1990.50 millions from Rs. 1091.60 millions in the quarter ended December 2022.Operating Profit saw a handsome growth to 3880.80 millions from 2226.10 millions in the quarter ended December 2022.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 15007.00 | 9325.80 | 60.92 | 44941.10 | 33293.80 | 34.98 | 47070.40 | 47687.20 | -1.29 |
| Other Income | 29.80 | 71.90 | -58.55 | 100.10 | 192.60 | -48.03 | 215.50 | 273.20 | -21.12 |
| PBIDT | 3880.80 | 2226.10 | 74.33 | 12393.30 | 9315.50 | 33.04 | 13067.50 | 15371.90 | -14.99 |
| Interest | 392.60 | 209.40 | 87.49 | 1046.70 | 665.70 | 57.23 | 958.60 | 659.20 | 45.42 |
| PBDT | 3488.20 | 2016.70 | 72.97 | 11346.60 | 8649.80 | 31.18 | 12108.90 | 14712.70 | -17.70 |
| Depreciation | 784.80 | 597.20 | 31.41 | 2200.30 | 1745.40 | 26.06 | 2354.80 | 1966.40 | 19.75 |
| PBT | 2703.40 | 1419.50 | 90.45 | 9146.30 | 6904.40 | 32.47 | 9754.10 | 12746.30 | -23.48 |
| TAX | 712.90 | 327.90 | 117.41 | 2565.30 | 1615.70 | 58.77 | 2253.20 | 3185.20 | -29.26 |
| Deferred Tax | 0.90 | -48.70 | -101.85 | -68.10 | 66.00 | -203.18 | -61.00 | -164.60 | -62.94 |
| PAT | 1990.50 | 1091.60 | 82.35 | 6581.00 | 5288.70 | 24.44 | 7500.90 | 9561.10 | -21.55 |
| Equity | 1077.30 | 1074.70 | 0.24 | 1077.30 | 1074.70 | 0.24 | 1074.70 | 1073.20 | 0.14 |
| PBIDTM(%) | 25.86 | 23.87 | 8.34 | 27.58 | 27.98 | -1.44 | 27.76 | 32.23 | -13.88 |
Laurus Labs - Quaterly Results
Publish Date: 30/01/2023
The turnover soared 60.92% to Rs. 15007.00 millions for the December 2022 quarter as compared to Rs. 9325.80 millions during the corresponding quarter last year.Net profit surges 82.35% to Rs. 1990.50 millions from Rs. 1091.60 millions in the quarter ended December 2022.The company reported a good operating profit of 3880.80 millions compared to 2226.10 millions of corresponding previous quarter.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 15007.00 | 9325.80 | 60.92 | 44941.10 | 33293.80 | 34.98 | 47070.40 | 47687.20 | -1.29 |
| Other Income | 29.80 | 71.90 | -58.55 | 100.10 | 192.60 | -48.03 | 215.50 | 273.20 | -21.12 |
| PBIDT | 3880.80 | 2226.10 | 74.33 | 12393.30 | 9315.50 | 33.04 | 13067.50 | 15371.90 | -14.99 |
| Interest | 392.60 | 209.40 | 87.49 | 1046.70 | 665.70 | 57.23 | 958.60 | 659.20 | 45.42 |
| PBDT | 3488.20 | 2016.70 | 72.97 | 11346.60 | 8649.80 | 31.18 | 12108.90 | 14712.70 | -17.70 |
| Depreciation | 784.80 | 597.20 | 31.41 | 2200.30 | 1745.40 | 26.06 | 2354.80 | 1966.40 | 19.75 |
| PBT | 2703.40 | 1419.50 | 90.45 | 9146.30 | 6904.40 | 32.47 | 9754.10 | 12746.30 | -23.48 |
| TAX | 712.90 | 327.90 | 117.41 | 2565.30 | 1615.70 | 58.77 | 2253.20 | 3185.20 | -29.26 |
| Deferred Tax | 0.90 | -48.70 | -101.85 | -68.10 | 66.00 | -203.18 | -61.00 | -164.60 | -62.94 |
| PAT | 1990.50 | 1091.60 | 82.35 | 6581.00 | 5288.70 | 24.44 | 7500.90 | 9561.10 | -21.55 |
| Equity | 1077.30 | 1074.70 | 0.24 | 1077.30 | 1074.70 | 0.24 | 1074.70 | 1073.20 | 0.14 |
| PBIDTM(%) | 25.86 | 23.87 | 8.34 | 27.58 | 27.98 | -1.44 | 27.76 | 32.23 | -13.88 |
Laurus Labs - Quaterly Results
Publish Date: 30/01/2023
The turnover soared 60.92% to Rs. 15007.00 millions for the December 2022 quarter as compared to Rs. 9325.80 millions during the corresponding quarter last year.Net profit surges 82.35% to Rs. 1990.50 millions from Rs. 1091.60 millions in the quarter ended December 2022.The company reported a good operating profit of 3880.80 millions compared to 2226.10 millions of corresponding previous quarter.
(Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202212 | 202112 | % Var | 202212 | 202112 | % Var | 202203 | 202103 | % Var | |
| Sales | 15007.00 | 9325.80 | 60.92 | 44941.10 | 33293.80 | 34.98 | 47070.40 | 47687.20 | -1.29 |
| Other Income | 29.80 | 71.90 | -58.55 | 100.10 | 192.60 | -48.03 | 215.50 | 273.20 | -21.12 |
| PBIDT | 3880.80 | 2226.10 | 74.33 | 12393.30 | 9315.50 | 33.04 | 13067.50 | 15371.90 | -14.99 |
| Interest | 392.60 | 209.40 | 87.49 | 1046.70 | 665.70 | 57.23 | 958.60 | 659.20 | 45.42 |
| PBDT | 3488.20 | 2016.70 | 72.97 | 11346.60 | 8649.80 | 31.18 | 12108.90 | 14712.70 | -17.70 |
| Depreciation | 784.80 | 597.20 | 31.41 | 2200.30 | 1745.40 | 26.06 | 2354.80 | 1966.40 | 19.75 |
| PBT | 2703.40 | 1419.50 | 90.45 | 9146.30 | 6904.40 | 32.47 | 9754.10 | 12746.30 | -23.48 |
| TAX | 712.90 | 327.90 | 117.41 | 2565.30 | 1615.70 | 58.77 | 2253.20 | 3185.20 | -29.26 |
| Deferred Tax | 0.90 | -48.70 | -101.85 | -68.10 | 66.00 | -203.18 | -61.00 | -164.60 | -62.94 |
| PAT | 1990.50 | 1091.60 | 82.35 | 6581.00 | 5288.70 | 24.44 | 7500.90 | 9561.10 | -21.55 |
| Equity | 1077.30 | 1074.70 | 0.24 | 1077.30 | 1074.70 | 0.24 | 1074.70 | 1073.20 | 0.14 |
| PBIDTM(%) | 25.86 | 23.87 | 8.34 | 27.58 | 27.98 | -1.44 | 27.76 | 32.23 | -13.88 |
Laurus Labs informs about presentation
Publish Date: 21/10/2022
Laurus Labs has informed that it enclosed the presentation to the Investors/Analysts on the Standalone and Consolidated Financial Results of the Company for the Quarter and half year ended September 30, 2022, for the Investors/Analysts call scheduled on October 21, 2022 @ 05.00 PM (IST), which was already intimated on October 13, 2022. The presentation is also being uploaded on the website of the Company www.lauruslabs.com.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs informs about press release
Publish Date: 21/10/2022
Laurus Labs has informed that it enclosed the Press Release on the financial results for the quarter and half year ended September 30, 2022.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs rises on entering into share subscription agreement with Ethan Energy India
Publish Date: 25/11/2022
This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant
Laurus Labs is currently trading at Rs. 457.90, up by 8.55 points or 1.90% from its previous closing of Rs. 449.35 on the BSE.
The scrip opened at Rs. 453.50 and has touched a high and low of Rs. 459.75 and Rs. 450.00 respectively. So far 32636 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 626.00 on 19-Apr-2022 and a 52 week low of Rs. 433.20 on 28-Jan-2022.
Last one week high and low of the scrip stood at Rs. 461.95 and Rs. 444.40 respectively. The current market cap of the company is Rs. 24616.43 crore.
The promoters holding in the company stood at 27.27%, while Institutions and Non-Institutions held 31.99% and 40.74% respectively.
Laurus Labs, as per the policy of the Government for captive consumption of power, has entered into Share Subscription agreement and Shareholders’ agreement on November 23, 2022 with Ethan Energy India for subscribing 7,40,000 Equity Shares of face value of Rs 10 each at a premium of Rs 42.70 which is equivalent to 26% of the paid up capital of Ethan Energy India. This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Laurus Labs informs about flash fire in manufacturing plant
Publish Date: 27/12/2022
Laurus Labs has informed that on the evening of 26th December 2022 flash fire occurred in one of the rooms in one manufacturing block of its API manufacturing plant (Unit 3), Jawaharlal Nehru Pharma City, Parawada, Anakapally district, Visakhapatnam, Andhra Pradesh. The operations in the other production blocks are running normally. Further, it has informed that two of regular employees and two contract employees have lost their lives after reaching hospital. One regular employee is in hospital and undergoing treatment. The company extended its full support to the families. The Company launched investigation into the incident. The Company estimates that no material impact on the operations.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs informs about disclosure
Publish Date: 10/02/2023
Laurus Labs has informed that the United States Food & Drug Administration (USFDA) today completed inspection of our formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh. The inspection was conducted from 6th February, 2023 to 10th February, 2023. It has been issued a Form 483 with two observations. The observations are procedural in nature. The Company will address the observations within stipulated timelines.
The above information is a part of company’s filings submitted to BSE.
Laurus Labs informs about analyst meeting
Publish Date: 13/03/2023
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the ‘Regulations’), Laurus Labs has informed that Analyst/Institutional Investor meeting is scheduled on March 13, 2023 with Motilal Oswal in the form of In-Person Meetings. No Unpublished Price Sensitive Information will be shared during the meetings
The above information is a part of company’s filings submitted to BSE.
Board Meeting
Publish Date: 21/10/2022
Quarterly Results & Interim Dividend
Ex Dividend
Publish Date: 10/05/2022
Rs.1.2000 per share (60%) Second Interim Dividend
Board Meeting
Publish Date: 28/04/2022
Interim Dividend & Audited Results
Board Meeting
Publish Date: 27/01/2022
Quarterly Results
Ex Dividend
Publish Date: 17/11/2021
Rs.0.8000 per share(40%)Interim Dividend
Board Meeting
Publish Date: 28/10/2021
Quarterly Results & Interim Dividend
Board Meeting
Publish Date: 29/07/2021
Quarterly Results
Ex Dividend
Publish Date: 11/05/2021
Rs.0.8000 per share (40%) Third Interim Dividend
Board Meeting
Publish Date: 29/04/2021
Third Interim Dividend & Audited Results
Laurus Labs enters into share subscription agreement with Ethan Energy India
Publish Date: 25/11/2022
This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant
Laurus Labs, as per the policy of the Government for captive consumption of power, has entered into Share Subscription agreement and Shareholders’ agreement on November 23, 2022 with Ethan Energy India for subscribing 7,40,000 Equity Shares of face value of Rs 10 each at a premium of Rs 42.70 which is equivalent to 26% of the paid up capital of Ethan Energy India. This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Laurus Labs reports 31% rise in Q3 consolidated net profit
Publish Date: 30/01/2023
Total consolidated income of the company increased by 49.53% to Rs 1,546.25 crore for the quarter under review
Laurus Labs has reported results for third quarter ended December 31, 2022.
The company has reported rise of 82.35% in its net profit at Rs 199.05 crore for Q3FY23 as compared to Rs 109.16 crore for the corresponding quarter previous year. Total income of the company increased by 60.01% to Rs 1,503.68 crore for the quarter under review as compared to Rs 939.77 crore for the same quarter in the previous year.
On the consolidated basis, the company has reported rise of 31.03% in its net profit at Rs 203.06 crore for Q3FY23 as compared to Rs 154.97 crore for the same quarter in the previous year. Total income of the company increased by 49.53% to Rs 1,546.25 crore for the quarter under review as compared to Rs 1,034.09 crore for the same quarter in the previous year.
Open A Free Demat Account
Sign Up
